501
|
Dunn AE, Dunn DJ, Macmillan A, Whan R, Stait-Gardner T, Price WS, Lim M, Boyer C. Spatial and temporal control of drug release through pH and alternating magnetic field induced breakage of Schiff base bonds. Polym Chem 2014. [DOI: 10.1039/c4py00150h] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A novel theranostic controlled drug delivery platform that binds the drug to the nanocarrier by utilising Schiff base bonds to achieve high spatial and temporal control over drug release.
Collapse
Affiliation(s)
- Alexander E. Dunn
- ARC Centre of Excellence for Functional Nanomaterials
- School of Chemical Engineering
- The University of New South Wales
- Sydney, Australia
- Australian Centre for NanoMedicine and Centre for Advanced Macromolecular Design
| | - Douglas J. Dunn
- ARC Centre of Excellence for Functional Nanomaterials
- School of Chemical Engineering
- The University of New South Wales
- Sydney, Australia
- Australian Centre for NanoMedicine and Centre for Advanced Macromolecular Design
| | - Alexander Macmillan
- Biomedical Imaging Facility
- Mark Wainwright Analytical Centre
- The University of New South Wales
- Sydney, Australia
| | - Renee Whan
- Biomedical Imaging Facility
- Mark Wainwright Analytical Centre
- The University of New South Wales
- Sydney, Australia
| | - Tim Stait-Gardner
- Nanoscale Organisation and Dynamics Group
- School of Science and Health
- University of Western Sydney
- Penrith, Australia
| | - William S. Price
- Nanoscale Organisation and Dynamics Group
- School of Science and Health
- University of Western Sydney
- Penrith, Australia
| | - May Lim
- ARC Centre of Excellence for Functional Nanomaterials
- School of Chemical Engineering
- The University of New South Wales
- Sydney, Australia
| | - Cyrille Boyer
- Australian Centre for NanoMedicine and Centre for Advanced Macromolecular Design
- School of Chemical Engineering
- The University of New South Wales
- Sydney, Australia
| |
Collapse
|
502
|
|
503
|
Bromfield SM, Posocco P, Chan CW, Calderon M, Guimond SE, Turnbull JE, Pricl S, Smith DK. Nanoscale self-assembled multivalent (SAMul) heparin binders in highly competitive, biologically relevant, aqueous media. Chem Sci 2014. [DOI: 10.1039/c4sc00298a] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
504
|
Tao Y, He J, Zhang M, Hao Y, Liu J, Ni P. Galactosylated biodegradable poly(ε-caprolactone-co-phosphoester) random copolymer nanoparticles for potent hepatoma-targeting delivery of doxorubicin. Polym Chem 2014. [DOI: 10.1039/c4py00024b] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A novel biocompatible and biodegradable poly(ε-caprolactone-co-phosphoester) random copolymer conjugated with galactosamine has been synthesized and used for hepatoma-targeting delivery of doxorubicin.
Collapse
Affiliation(s)
- Yunfeng Tao
- College of Chemistry
- Chemical Engineering and Materials Science
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Soochow University
- Suzhou 215123, P. R. China
| | - Jinlin He
- College of Chemistry
- Chemical Engineering and Materials Science
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Soochow University
- Suzhou 215123, P. R. China
| | - Mingzu Zhang
- College of Chemistry
- Chemical Engineering and Materials Science
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Soochow University
- Suzhou 215123, P. R. China
| | - Ying Hao
- College of Chemistry
- Chemical Engineering and Materials Science
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Soochow University
- Suzhou 215123, P. R. China
| | - Jian Liu
- Institute of Functional Nano & Soft Materials (FUNSOM)
- Collaborative Innovation Center of Suzhou Nano Science and Technology
- Soochow University
- Suzhou, P. R. China
| | - Peihong Ni
- College of Chemistry
- Chemical Engineering and Materials Science
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application
- Soochow University
- Suzhou 215123, P. R. China
| |
Collapse
|
505
|
Karagoz B, Esser L, Duong HT, Basuki JS, Boyer C, Davis TP. Polymerization-Induced Self-Assembly (PISA) – control over the morphology of nanoparticles for drug delivery applications. Polym Chem 2014. [DOI: 10.1039/c3py01306e] [Citation(s) in RCA: 251] [Impact Index Per Article: 25.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
506
|
Faucon A, Maldiney T, Clément O, Hulin P, Nedellec S, Robard M, Gautier N, De Meulenaere E, Clays K, Orlando T, Lascialfari A, Fiorini-Debuisschert C, Fresnais J, Ishow E. Highly cohesive dual nanoassemblies for complementary multiscale bioimaging. J Mater Chem B 2014; 2:7747-7755. [DOI: 10.1039/c4tb01199f] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Core–shell nanoarchitectures made of non-doped fluorescent organic platforms capped with magnetic nanoparticles display high bioimaging performances.
Collapse
Affiliation(s)
- Adrien Faucon
- CEISAM – UMR CNRS 6230
- Université de Nantes
- 44322 Nantes, France
| | - Thomas Maldiney
- Paris Cardiovascular Research Center – PARCC
- Université Paris Descartes
- INSERM U970
- 75015 Paris, France
| | - Olivier Clément
- Paris Cardiovascular Research Center – PARCC
- Université Paris Descartes
- INSERM U970
- 75015 Paris, France
| | | | | | | | | | - Evelien De Meulenaere
- Department of Chemistry
- KULeuven
- 3001 Heverlee, Belgium
- Department of Bioscience Engineering
- KULeuven
| | - Koen Clays
- Department of Chemistry
- KULeuven
- 3001 Heverlee, Belgium
| | - Tomas Orlando
- Department of Physics and INSTM
- Università di Pavia
- 27100 Pavia, Italy
| | | | | | - Jérôme Fresnais
- PECSA – UMR CNRS 7195
- Université Pierre et Marie Curie
- 75005 Paris, France
| | - Eléna Ishow
- CEISAM – UMR CNRS 6230
- Université de Nantes
- 44322 Nantes, France
| |
Collapse
|
507
|
Phillips DJ, Patterson JP, O'Reilly RK, Gibson MI. Glutathione-triggered disassembly of isothermally responsive polymer nanoparticles obtained by nanoprecipitation of hydrophilic polymers. Polym Chem 2014. [DOI: 10.1039/c3py00991b] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Nanoparticles obtained by the nanoprecipitation of responsive polymers are shown to specifically and rapidly disassemble into hydrophilic polymer chains in the presence of intracellular concentrations of glutathione.
Collapse
|
508
|
|
509
|
Matini T, Francini N, Battocchio A, Spain SG, Mantovani G, Vicent MJ, Sanchis J, Gallon E, Mastrotto F, Salmaso S, Caliceti P, Alexander C. Synthesis and characterization of variable conformation pH responsive block co-polymers for nucleic acid delivery and targeted cell entry. Polym Chem 2014. [DOI: 10.1039/c3py00744h] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
510
|
Conner J. Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis. ACTA ACUST UNITED AC 2014. [DOI: 10.7243/2054-989x-1-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
511
|
De Nicola A, Hezaveh S, Zhao Y, Kawakatsu T, Roccatano D, Milano G. Micellar drug nanocarriers and biomembranes: how do they interact? Phys Chem Chem Phys 2014; 16:5093-105. [DOI: 10.1039/c3cp54242d] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
512
|
Les KA, Mohamed-Ahmed AHA, Balan S, Choi JW, Martin D, Yardley V, Powell K, Godwin A, Brocchini S. Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases. Polym Chem 2014. [DOI: 10.1039/c3py01051a] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
513
|
Khan AR, Magnusson JP, Watson S, Grabowska AM, Wilkinson RW, Alexander C, Pritchard D. Camptothecin prodrug block copolymer micelles with high drug loading and target specificity. Polym Chem 2014. [DOI: 10.1039/c4py00369a] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The effects of a novel functional reducible camptothecin (CPT) block copolymer conjugate, targeting luteinizing hormone releasing hormone receptor (LHRHR) were evaluated against differing LHRHR expressing tumour cell lines and immune populations.
Collapse
Affiliation(s)
- Adnan R. Khan
- School of Pharmacy
- University of Nottingham
- University Park
- Nottingham NG7 2RD, UK
- AstraZeneca
| | | | - Sue Watson
- Pre-Clinical Oncology
- School of Medical and Surgical Sciences
- Queens Medical Centre
- University of Nottingham
- , UK
| | - Anna M. Grabowska
- Pre-Clinical Oncology
- School of Medical and Surgical Sciences
- Queens Medical Centre
- University of Nottingham
- , UK
| | | | - Cameron Alexander
- School of Pharmacy
- University of Nottingham
- University Park
- Nottingham NG7 2RD, UK
| | - David Pritchard
- School of Pharmacy
- University of Nottingham
- University Park
- Nottingham NG7 2RD, UK
| |
Collapse
|
514
|
Crucho CIC, Barros MT. Surfactant-free polymeric nanoparticles composed of PEG, cholic acid and a sucrose moiety. J Mater Chem B 2014; 2:3946-3955. [DOI: 10.1039/c3tb21632b] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
New amphiphilic polymers synthesized from a sucrose-containing conjugate exhibited interesting self-assembly properties in water. Owing to their amphiphilic characteristics polymeric nanoparticles were prepared by a nanoprecipitation method without any surfactants. These nanoparticles formulated with biocompatible building blocks can be considered a potential candidate for drug delivery applications.
Collapse
Affiliation(s)
- Carina I. C. Crucho
- REQUIMTE/CQFB
- Departamento de Química
- Faculdade de Ciências e Tecnologia
- Universidade Nova de Lisboa
- , Portugal
| | - M. Teresa Barros
- REQUIMTE/CQFB
- Departamento de Química
- Faculdade de Ciências e Tecnologia
- Universidade Nova de Lisboa
- , Portugal
| |
Collapse
|
515
|
Vanić Ž, Škalko-Basnet N. Mucosal nanosystems for improved topical drug delivery: vaginal route of administration. J Drug Deliv Sci Technol 2014. [DOI: 10.1016/s1773-2247(14)50085-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
516
|
Poma A, Guerreiro A, Caygill S, Moczko E, Piletsky S. Automatic reactor for solid-phase synthesis of molecularly imprinted polymeric nanoparticles (MIP NPs) in water. RSC Adv 2014; 4:4203-4206. [PMID: 26722622 DOI: 10.1039/c3ra46838k] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
We report the development of an automated chemical reactor for solid-phase synthesis of MIP NPs in water. Operational parameters are under computer control, requiring minimal operator intervention. In this study, "ready for use" MIP NPs with sub-nanomolar affinity are prepared against pepsin A, trypsin and α-amylase in only 4 hours.
Collapse
Affiliation(s)
- Alessandro Poma
- Cranfield Health, Cranfield University, Cranfield, MK43 0AL, United Kingdom
| | - Antonio Guerreiro
- Cranfield Health, Cranfield University, Cranfield, MK43 0AL, United Kingdom
| | - Sarah Caygill
- Cranfield Health, Cranfield University, Cranfield, MK43 0AL, United Kingdom
| | - Ewa Moczko
- Cranfield Health, Cranfield University, Cranfield, MK43 0AL, United Kingdom
| | - Sergey Piletsky
- Cranfield Health, Cranfield University, Cranfield, MK43 0AL, United Kingdom
| |
Collapse
|
517
|
Videira M, Arranja A, Rafael D, Gaspar R. Preclinical development of siRNA therapeutics: towards the match between fundamental science and engineered systems. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2013; 10:689-702. [PMID: 24333589 DOI: 10.1016/j.nano.2013.11.018] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Revised: 11/21/2013] [Accepted: 11/24/2013] [Indexed: 12/14/2022]
Abstract
UNLABELLED The evolution of synthetic RNAi faces the paradox of interfering with the human biological environment. Due to the fact that all cell physiological processes can be target candidates, silencing a precise biological pathway could be challenging if target selectivity is not properly addressed. Molecular biology has provided scientific tools to suppress some of the most critical issues in gene therapy, while setting the standards for siRNA clinical application. However, the protein down-regulation through the mRNA silencing is intimately related to the sequence-specific siRNA ability to interact accurately with the potential target. Moreover, its in vivo biological fate is highly dependent on the successful design of a vehicle able to overcome both extracellular and intracellular barriers. Anticipating a great deal of innovation, crucial to meet the challenges involved in the RNAi therapeutics, the present review intends to build up a synopsis on the delivery strategies currently developed. FROM THE CLINICAL EDITOR This review discusses recent progress and pertinent limiting factors related to the use of siRNA-s as efficient protein-specific "silencing" agents, focusing on targeted delivery not only to cells of interest, but to the proper intracellular destination.
Collapse
Affiliation(s)
- M Videira
- iMed.UL - Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Av. Professor Gama Pinto, 1649-003 Lisbon, Portugal.
| | - A Arranja
- iMed.UL - Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Av. Professor Gama Pinto, 1649-003 Lisbon, Portugal
| | - D Rafael
- iMed.UL - Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Av. Professor Gama Pinto, 1649-003 Lisbon, Portugal
| | - R Gaspar
- iMed.UL - Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Av. Professor Gama Pinto, 1649-003 Lisbon, Portugal
| |
Collapse
|
518
|
Vllasaliu D, Fowler R, Stolnik S. PEGylated nanomedicines: recent progress and remaining concerns. Expert Opin Drug Deliv 2013; 11:139-54. [DOI: 10.1517/17425247.2014.866651] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
519
|
Seib FP, Jones GT, Rnjak-Kovacina J, Lin Y, Kaplan DL. pH-dependent anticancer drug release from silk nanoparticles. Adv Healthc Mater 2013; 2:1606-11. [PMID: 23625825 DOI: 10.1002/adhm.201300034] [Citation(s) in RCA: 155] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2013] [Revised: 03/04/2013] [Indexed: 11/06/2022]
Abstract
Silk has traditionally been used as a suture material because of its excellent mechanical properties and biocompatibility. These properties have led to the development of different silk-based material formats for tissue engineering and regenerative medicine. Although there have been a small number of studies about the use of silk particles for drug delivery, none of these studies have assessed the potential of silk to act as a stimulus-responsive anticancer nanomedicine. This report demonstrates that an acetone precipitation of silk allows the formation of uniform silk nanoparticles (98 nm diameter, polydispersity index 0.109), with an overall negative surface charge (-33.6 ± 5.8 mV), in a single step. Silk nanoparticles are readily loaded with doxorubicin (40 ng doxorubicin/μg silk) and show pH-dependent release (pH 4.5≫ 6.0 > 7.4). In vitro studies with human breast cancer cell lines demonstrates that the silk nanoparticles are not cytotoxic (IC50 > 120 μg mL(-1) ) and that doxorubicin-loaded silk nanoparticles are able to overcome drug resistance mechanisms. Live cell fluorescence microscopy studies show endocytic uptake and lysosomal accumulation of silk nanoparticles. In summary, the pH-dependent drug release and lysosomal accumulation of silk nanoparticles demonstrate the ability of drug-loaded silk nanoparticles to serve as a lysosomotropic anticancer nanomedicine.
Collapse
Affiliation(s)
- F Philipp Seib
- Tufts University, Department of Biomedical Engineering, 4 Colby Street, Medford, MA 02155, USA
| | | | | | | | | |
Collapse
|
520
|
Denora N, Laquintana V, Lopalco A, Iacobazzi RM, Lopedota A, Cutrignelli A, Iacobellis G, Annese C, Cascione M, Leporatti S, Franco M. In vitro targeting and imaging the translocator protein TSPO 18-kDa through G(4)-PAMAM–FITC labeled dendrimer. J Control Release 2013; 172:1111-25. [DOI: 10.1016/j.jconrel.2013.09.024] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2013] [Revised: 09/15/2013] [Accepted: 09/18/2013] [Indexed: 01/25/2023]
|
521
|
de la Iglesia D, Cachau RE, García-Remesal M, Maojo V. Nanoinformatics knowledge infrastructures: bringing efficient information management to nanomedical research. COMPUTATIONAL SCIENCE & DISCOVERY 2013; 6:014011. [PMID: 24932210 PMCID: PMC4053539 DOI: 10.1088/1749-4699/6/1/014011] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Nanotechnology represents an area of particular promise and significant opportunity across multiple scientific disciplines. Ongoing nanotechnology research ranges from the characterization of nanoparticles and nanomaterials to the analysis and processing of experimental data seeking correlations between nanoparticles and their functionalities and side effects. Due to their special properties, nanoparticles are suitable for cellular-level diagnostics and therapy, offering numerous applications in medicine, e.g. development of biomedical devices, tissue repair, drug delivery systems and biosensors. In nanomedicine, recent studies are producing large amounts of structural and property data, highlighting the role for computational approaches in information management. While in vitro and in vivo assays are expensive, the cost of computing is falling. Furthermore, improvements in the accuracy of computational methods (e.g. data mining, knowledge discovery, modeling and simulation) have enabled effective tools to automate the extraction, management and storage of these vast data volumes. Since this information is widely distributed, one major issue is how to locate and access data where it resides (which also poses data-sharing limitations). The novel discipline of nanoinformatics addresses the information challenges related to nanotechnology research. In this paper, we summarize the needs and challenges in the field and present an overview of extant initiatives and efforts.
Collapse
Affiliation(s)
- D de la Iglesia
- Biomedical Informatics Group, Dept. Inteligencia Artificial, Facultad de Informatica, Universidad Politecnica de Madrid, 28660, Boadilla del Monte, Madrid, Spain
| | - R E Cachau
- Advanced Biomedical Computing Center, National Cancer Institute, SAIC-Frederick Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - M García-Remesal
- Biomedical Informatics Group, Dept. Inteligencia Artificial, Facultad de Informatica, Universidad Politecnica de Madrid, 28660, Boadilla del Monte, Madrid, Spain
| | - V Maojo
- Biomedical Informatics Group, Dept. Inteligencia Artificial, Facultad de Informatica, Universidad Politecnica de Madrid, 28660, Boadilla del Monte, Madrid, Spain
| |
Collapse
|
522
|
Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine (Lond) 2013; 8:773-84. [PMID: 23656264 DOI: 10.2217/nnm.13.48] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Nanotechnology is proven to provide certain benefits in drug delivery by improving solubility, increasing uptake to target sites and changing pharmacokinetics profiles of traditional drugs. Since properties of many materials change tremendously at the nanoscale levels, nanotechnology is also being explored in various industrial applications. As such, nanoparticles are rapidly entering various areas of industry, biology and medicine. The benefits of using nanotechnology for industrial and biomedical applications are often tempered by concerns about the safety of these new materials. One such area of concern includes their effect on the immune system. While nanoparticle interactions with various constituents of the immune system have been reviewed before, little attention was given to nanoparticle effects on the blood coagulation system. Nanoparticle interface with the blood coagulation system may lead to either benefits to the host or adverse reactions. This article reviews recent advances in our understanding of nanoparticle interactions with plasma coagulation factors, platelets, endothelial cells and leukocytes. Part I is focused on desirable interactions between nanoparticles and the coagulation system, and discusses benefits of using nanotechnology to intervene in coagulation disorders. Undesirable interactions posing safety concerns are covered in part II, which will be published in the June issue of Nanomedicine.
Collapse
Affiliation(s)
- Anna N Ilinskaya
- Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick Inc., NCI-Frederick, 1050 Boyles Street, Building 469, Frederick, MD 21702, USA
| | | |
Collapse
|
523
|
Ehmann F, Sakai-Kato K, Duncan R, Hernán Pérez de la Ossa D, Pita R, Vidal JM, Kohli A, Tothfalusi L, Sanh A, Tinton S, Robert JL, Silva Lima B, Amati MP. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond) 2013; 8:849-56. [PMID: 23656268 DOI: 10.2217/nnm.13.68] [Citation(s) in RCA: 91] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Over the last three decades many first-generation nanomedicines have successfully entered routine clinical use and it is now important for medicines regulatory agencies to consider the mechanisms needed to ensure safe introduction of 'follow-on' nanomedicine products, 'nanosimilars'. Moreover, drug regulators need to ensure that 'next'-generation nanomedicines enter clinical development and consequently the market in a safe and timely way for the benefit of public health. Here we review recent European Medicines Agency activities that relate to the effective development and evaluation of nanomedicine products while keeping patient and consumer safety at the forefront.
Collapse
Affiliation(s)
- Falk Ehmann
- Nanomedicines Drafting Group, European Medicines Agency, 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
524
|
Lin CY, Pitt WG. Acoustic droplet vaporization in biology and medicine. BIOMED RESEARCH INTERNATIONAL 2013; 2013:404361. [PMID: 24350267 PMCID: PMC3853706 DOI: 10.1155/2013/404361] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 09/17/2013] [Accepted: 10/03/2013] [Indexed: 01/20/2023]
Abstract
This paper reviews the literature regarding the use of acoustic droplet vaporization (ADV) in clinical applications of imaging, embolic therapy, and therapeutic delivery. ADV is a physical process in which the pressure waves of ultrasound induce a phase transition that causes superheated liquid nanodroplets to form gas bubbles. The bubbles provide ultrasonic imaging contrast and other functions. ADV of perfluoropentane was used extensively in imaging for preclinical trials in the 1990s, but its use declined rapidly with the advent of other imaging agents. In the last decade, ADV was proposed and explored for embolic occlusion therapy, drug delivery, aberration correction, and high intensity focused ultrasound (HIFU) sensitization. Vessel occlusion via ADV has been explored in rodents and dogs and may be approaching clinical use. ADV for drug delivery is still in preclinical stages with initial applications to treat tumors in mice. Other techniques are still in preclinical studies but have potential for clinical use in specialty applications. Overall, ADV has a bright future in clinical application because the small size of nanodroplets greatly reduces the rate of clearance compared to larger contrast agent bubbles and yet provides the advantages of ultrasonographic contrast, acoustic cavitation, and nontoxicity of conventional perfluorocarbon contrast agent bubbles.
Collapse
Affiliation(s)
- Chung-Yin Lin
- Department of Chemical Engineering, Brigham Young University, Provo, UT 84602, USA
- Department of Neurosurgery, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
- Division of Clinical Toxicology, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
| | - William G. Pitt
- Department of Chemical Engineering, Brigham Young University, Provo, UT 84602, USA
| |
Collapse
|
525
|
Gaillard PJ, Visser CC, de Boer M, Appeldoorn CCM, Rip J. Blood-to-Brain Drug Delivery Using Nanocarriers. ACTA ACUST UNITED AC 2013. [DOI: 10.1007/978-1-4614-9105-7_15] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
526
|
Janus cyclic peptide–polymer nanotubes. Nat Commun 2013; 4:2780. [DOI: 10.1038/ncomms3780] [Citation(s) in RCA: 83] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Accepted: 10/16/2013] [Indexed: 12/23/2022] Open
|
527
|
Wang S, Su R, Nie S, Sun M, Zhang J, Wu D, Moustaid-Moussa N. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J Nutr Biochem 2013; 25:363-76. [PMID: 24406273 DOI: 10.1016/j.jnutbio.2013.10.002] [Citation(s) in RCA: 255] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2013] [Revised: 09/04/2013] [Accepted: 10/14/2013] [Indexed: 02/07/2023]
Abstract
Nanotechnology is an innovative approach that has potential applications in nutraceutical research. Phytochemicals have promising potential for maintaining and promoting health, as well as preventing and potentially treating some diseases. However, the generally low solubility, stability, bioavailability and target specificity, together with the side effects seen when used at high levels, have limited their application. Indeed, nanoparticles can increase solubility and stability of phytochemicals, enhance their absorption, protect them from premature degradation in the body and prolong their circulation time. Moreover, these nanoparticles exhibit high differential uptake efficiency in the target cells (or tissue) over normal cells (or tissue) through preventing them from prematurely interacting with the biological environment, enhanced permeation and retention effect in disease tissues and improving their cellular uptake, resulting in decreased toxicity, In this review, we outline the commonly used biocompatible and biodegradable nanoparticles including liposomes, emulsions, solid lipid nanoparticles, nanostructured lipid carriers, micelles and poly(lactic-co-glycolic acid) nanoparticles. We then summarize studies that have used these nanoparticles as carriers for epigallocatechin gallate, quercetin, resveratrol and curcumin administration to enhance their aqueous solubility, stability, bioavailability, target specificity and bioactivities.
Collapse
Affiliation(s)
- Shu Wang
- Nutritional Sciences program, Texas Tech University, Box 41240, Lubbock, TX 79409-1240, USA.
| | - Rui Su
- Nutritional Sciences program, Texas Tech University, Box 41240, Lubbock, TX 79409-1240, USA
| | - Shufang Nie
- Nutritional Sciences program, Texas Tech University, Box 41240, Lubbock, TX 79409-1240, USA
| | - Ming Sun
- Nutritional Sciences program, Texas Tech University, Box 41240, Lubbock, TX 79409-1240, USA
| | - Jia Zhang
- Nutritional Sciences program, Texas Tech University, Box 41240, Lubbock, TX 79409-1240, USA
| | - Dayong Wu
- Nutritional Immunology Laboratory, JM USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
| | - Naima Moustaid-Moussa
- Nutritional Sciences program, Texas Tech University, Box 41240, Lubbock, TX 79409-1240, USA
| |
Collapse
|
528
|
Andrade F, Rafael D, Videira M, Ferreira D, Sosnik A, Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv Drug Deliv Rev 2013; 65:1816-27. [PMID: 23932923 PMCID: PMC7103277 DOI: 10.1016/j.addr.2013.07.020] [Citation(s) in RCA: 140] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Accepted: 07/18/2013] [Indexed: 12/22/2022]
Abstract
Used since ancient times especially for the local treatment of pulmonary diseases, lungs and airways are a versatile target route for the administration of both local and systemic drugs. Despite the existence of different platforms and devices for the pulmonary administration of drugs, only a few formulations are marketed, partly due to physiological and technological limitations. Respiratory infections represent a significant burden to health systems worldwide mainly due to intrahospital infections that more easily affect immune-compromised patients. Moreover, tuberculosis (TB) is an endemic infectious disease in many developing nations and it has resurged in the developed world associated with the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic. Currently, medicine faces the specter of antibiotic resistance. Besides the development of new anti-infectious drugs, the development of innovative and more efficient delivery systems for drugs that went off patent appears as a promising strategy pursued by the pharmaceutical industry to improve the therapeutic outcomes and to prolong the utilities of their intellectual property portfolio. In this context, nanotechnology-based drug delivery systems (nano-DDS) emerged as a promising approach to circumvent the limitations of conventional formulations and to treat drug resistance, opening the hypothesis for new developments in this area.
Collapse
|
529
|
Liu X, Huang N, Wang H, Li H, Jin Q, Ji J. The effect of ligand composition on the in vivo fate of multidentate poly(ethylene glycol) modified gold nanoparticles. Biomaterials 2013; 34:8370-81. [DOI: 10.1016/j.biomaterials.2013.07.059] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Accepted: 07/18/2013] [Indexed: 10/26/2022]
|
530
|
Akinc A, Battaglia G. Exploiting endocytosis for nanomedicines. Cold Spring Harb Perspect Biol 2013; 5:a016980. [PMID: 24186069 DOI: 10.1101/cshperspect.a016980] [Citation(s) in RCA: 142] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In this article, we briefly review the endocytic pathways used by cells, pointing out their defining characteristics and highlighting physical limitations that may direct the internalization of nanoparticles to a subset of these pathways. A more detailed description of these pathways is presented in the literature. We then focus on the endocytosis of nanomedicines and present how various nanomaterial parameters impact these endocytic processes. This topic is an area of active research, motivated by the recognition that an improved understanding of how nanomaterials interact at the molecular, cellular, and whole-organism level will lead to the design of better nanomedicines in the future. Next, we briefly review some of the important nanomedicines already on the market or in clinical development that serve to exemplify how endocytosis can be exploited for medical benefit. Finally, we present some key unanswered questions and remaining challenges to be addressed by the field.
Collapse
Affiliation(s)
- Akin Akinc
- Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142
| | | |
Collapse
|
531
|
Abstract
Significant progress has been made in nanoscale drugs and delivery systems employing diverse chemical formulations to facilitate the rate of drug delivery and to improve its pharmacokinetics. Biocompatible nanomaterials have been used as biological markers, contrast agents for imaging, healthcare products, pharmaceuticals, drug-delivery systems as well as in detection, diagnosis and treatment of various types of diseases. The classification of drug delivery nanosystems (DDnSs) is a crucial issue and fundamental efforts on this subject are missing from the literature. This article deals with the classification of DDnSs with a modulatory controlled release profile (MCR) denoted as modulatory controlled release nanosystems (MCRnSs). Conventional (c) and advanced (a) DDnSs are denoted by the acronyms cDDnSs and aDDnSs, and can be composed of a single or more than one biomaterials, respectively. The classification was based on their characteristics such as: surface functionality (f), the nature of biomaterials used and the kind of interactions between biomaterials. The aDDnSs can be classified as hybridic (Hy-) or chimeric (Chi-) based on the nature - same or different respectively - of biomaterials and inorganic materials used. The nature of the elements used for producing advanced biomaterials is of great importance and medicinal chemistry contributes effectively to the production of aDDnSs.
Collapse
Affiliation(s)
- Costas Demetzos
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Panepistimioupolis Zografou, University of Athens , Athens , Greece
| | | |
Collapse
|
532
|
|
533
|
Zoabi N, Golani-Armon A, Zinger A, Reshef M, Yaari Z, Vardi-Oknin D, Shatsberg Z, Shomar A, Shainsky-Roitman J, Schroeder A. The Evolution of Tumor-Targeted Drug Delivery: From the EPR Effect to Nanoswimmers. Isr J Chem 2013. [DOI: 10.1002/ijch.201300061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
534
|
Holley AC, Ray JG, Wan W, Savin DA, McCormick CL. Endolytic, pH-responsive HPMA-b-(L-Glu) copolymers synthesized via sequential aqueous RAFT and ring-opening polymerizations. Biomacromolecules 2013; 14:3793-9. [PMID: 24044682 DOI: 10.1021/bm401205y] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
A facile synthetic pathway for preparing block copolymers with pH-responsive L-glutamic acid segments for membrane disruption is reported. Aqueous reversible addition-fragmentation chain transfer (aRAFT) polymerization was first used to prepare biocompatible, nonimmunogenic poly[N-(2-hydroxypropyl)methacrylamide]. This macro chain transfer agent (CTA) was then converted into a macroinitiator via simultaneous aminolysis and thiol-ene Michael addition using the primary amine substituted N-(3-aminopropyl)methacrylamide. This macroinitiator was subsequently utilized in the ring-opening polymerization of the N-carboxyanhydride monomer of γ-benzyl-L-glutamate. After deprotection, the pH-dependent coil-to-helix transformations of the resulting HPMA-b-(L-Glu) copolymers were monitored via circular dichroism spectroscopy. HPMA segments confer water solubility and biocompatibility while the L-glutamic acid repeats provide reversible coil-to-helix transitions at endosomal pH values (~5-6). The endolytic properties of these novel [HPMA-b-(L-Glu)] copolymers and their potential as modular components in drug carrier constructs was demonstrated utilizing red blood cell hemolysis and fluorescein release from POPC vesicles.
Collapse
Affiliation(s)
- Andrew C Holley
- The Department of Polymer Science and Engineering and §The Department of Chemistry and Biochemistry, The University of Southern Mississippi , Hattiesburg, Mississippi 39406, United States
| | | | | | | | | |
Collapse
|
535
|
Bonini M, Berti D, Baglioni P. Nanostructures for magnetically triggered release of drugs and biomolecules. Curr Opin Colloid Interface Sci 2013. [DOI: 10.1016/j.cocis.2013.07.007] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
536
|
Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Adv Drug Deliv Rev 2013; 65:1316-30. [PMID: 23415951 DOI: 10.1016/j.addr.2013.01.001] [Citation(s) in RCA: 238] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Revised: 12/08/2012] [Accepted: 01/30/2013] [Indexed: 12/21/2022]
Abstract
Drugs are introduced into the body by numerous routes such as enteral (oral, sublingual and rectum administration), parenteral (intravascular, intramuscular, subcutaneous and inhalation administration), or topical (skin and mucosal membranes). Each route has specific purposes, advantages and disadvantages. Today, the oral route remains the preferred one for different reasons such as ease and compliance by patients. Several nanoformulated drugs have been already approved by the FDA, such as Abelcet®, Doxil®, Abraxane® or Vivagel®(Starpharma) which is an anionic G4-poly(L-lysine)-type dendrimer showing potent topical vaginal microbicide activity. Numerous biochemical studies, as well as biological and pharmacological applications of both dendrimer based products (dendrimers as therapeutic compounds per se, like Vivagel®) and dendrimers as drug carriers (covalent conjugation or noncovalent encapsulation of drugs) were described. It is widely known that due to their outstanding physical and chemical properties, dendrimers afforded improvement of corresponding carried-drugs as dendrimer-drug complexes or conjugates (versus plain drug) such as biodistribution and pharmacokinetic behaviors. The purpose of this manuscript is to review the recent progresses of dendrimers as nanoscale drug delivery systems for the delivery of drugs using enteral, parenteral and topical routes. In particular, we focus our attention on the emerging and promising routes such as oral, transdermal, ocular and transmucosal routes using dendrimers as delivery systems.
Collapse
|
537
|
van der Meel R, Vehmeijer LJC, Kok RJ, Storm G, van Gaal EVB. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev 2013; 65:1284-98. [PMID: 24018362 DOI: 10.1016/j.addr.2013.08.012] [Citation(s) in RCA: 277] [Impact Index Per Article: 25.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2013] [Revised: 08/09/2013] [Accepted: 08/29/2013] [Indexed: 12/25/2022]
Abstract
Since the introduction of Doxil® on the market nearly 20years ago, a number of nanomedicines have become part of treatment regimens in the clinic. With the exception of antibody-drug conjugates, these nanomedicines are all devoid of targeting ligands and rely solely on their physicochemical properties and the (patho)physiological processes in the body for their biodistribution and targeting capability. At the same time, many preclinical studies have reported on nanomedicines exposing targeting ligands, or ligand-targeted nanomedicines, yet none of these have been approved at this moment. In the present review, we provide a concise overview of 13 ligand-targeted particulate nanomedicines (ligand-targeted PNMs) that have progressed into clinical trials. The progress of each ligand-targeted PNM is discussed based on available (pre)clinical data. Main conclusions of these analyses are that (a) ligand-targeted PNMs have proven to be safe and efficacious in preclinical models; (b) the vast majority of ligand-targeted PNMs is generated for the treatment of cancer; (c) contribution of targeting ligands to the PNM efficacy is not unambiguously proven; and (d) targeting ligands do not cause localization of the PNM within the target tissue, but rather provide benefits in terms of target cell internalization and target tissue retention once the PNM has arrived at the target site. Increased understanding of the in vivo fate and interactions of the ligand-targeted PNMs with proteins and cells in the human body is mandatory to rationally advance the clinical translation of ligand-targeted PNMs. Future perspectives for ligand-targeted PNM approaches include the delivery of drugs that are unable or inefficient in passing cellular membranes, treatment of drug resistant tumors, targeting of the tumor blood supply, the generation of targeted vaccines and nanomedicines that are able to cross the blood-brain barrier.
Collapse
Affiliation(s)
- Roy van der Meel
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
| | | | | | | | | |
Collapse
|
538
|
Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother Pharmacol 2013; 72:417-27. [PMID: 23797686 PMCID: PMC3718995 DOI: 10.1007/s00280-013-2209-7] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Accepted: 05/31/2013] [Indexed: 12/12/2022]
Abstract
Purpose Intravenously (i.v.) administered nanomedicines have the potential for tumour targeting due to the enhanced permeability and retention (EPR) effect, but in vivo tumour models are rarely calibrated with respect to functional vascular permeability and/or mechanisms controlling intratumoural drug release. Here the effect of tumour type and tumour size on EPR-mediated tumour localisation and cathepsin B-mediated drug release was studied. Methods Evans Blue (10 mg/kg) and an N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer–doxorubicin (Dox) conjugate (FCE28068) (5 mg/kg Dox-equiv) were used as probes and tumour levels (and Dox release) measured at 1 h after i.v. administration in a panel of murine and human xenograft tumours. Results Evans Blue and FCE28068 displayed similar tumour levels in the range of 2–18 % dose/g at 1 h for B16F10 and L1210. Approximately half of the tumour models evaluated exhibited tumour size-dependent accumulation of FCE28068; smaller tumours had the highest accumulation. Administration of free Dox (5 mg/kg) produced tumour levels of <2.5 % dose/g independent of tumour size. Whereas the degree of EPR-mediated targeting showed ~12-fold difference across the tumour models evaluated, Dox release from FCE28068 at 1 h displayed ~200-fold variation. Conclusions Marked heterogeneity was seen in terms of EPR effect and Dox release rate, underlining the need to carefully calibrate tumour models used to benchmark nanomedicines against known relevant standard agents and for optimal development of strategies for late pre-clinical and clinical development. Electronic supplementary material The online version of this article (doi:10.1007/s00280-013-2209-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Ruth Duncan
- Centre for Polymer Therapeutics, The School of Pharmacy, 29-39 Brunswick Square, London, UK.
| | | | | | | | | | | |
Collapse
|
539
|
Fuhrmann K, Połomska A, Aeberli C, Castagner B, Gauthier MA, Leroux JC. Modular design of redox-responsive stabilizers for nanocrystals. ACS NANO 2013; 7:8243-8250. [PMID: 23968310 DOI: 10.1021/nn4037317] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Many potent drugs are difficult to administer intravenously due to poor aqueous solubility. A common approach for addressing this issue is to process them into colloidal dispersions known as "nanocrystals" (NCs). However, NCs possess high-energy surfaces that must be stabilized with surfactants to prevent aggregation. An optimal surfactant should have high affinity for the nanocrystal's surface to stabilize it, but may also include a trigger mechanism that could offer the possibility of altering size distribution and uptake of the NC. This study presents a modular and systematic strategy for optimizing the affinity of polymeric stabilizers for drug nanocrystals both before and after oxidation (i.e., the selected trigger), thus allowing for the optimal responsiveness for a given application to be identified. A library of 10 redox-responsive polymer stabilizers was prepared by postpolymerization modification, using the thiol-yne reaction, of two parent block copolymers. The stabilizing potential of these polymers for paclitaxel NCs is presented as well as the influence of oxidation on size and dissolution following exposure to reactive oxygen species (ROS), which are strongly associated with chronic inflammation and cancer. Owing to the versatility of postpolymerization modification, this contribution provides general tools for preparing triggered-sheddable stabilizing coatings for nanoparticles.
Collapse
Affiliation(s)
- Kathrin Fuhrmann
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich (ETH Zürich), Wolfgang-Pauli-Straße 10, 8093 Zurich, Switzerland
| | | | | | | | | | | |
Collapse
|
540
|
Kumar A, Chen F, Mozhi A, Zhang X, Zhao Y, Xue X, Hao Y, Zhang X, Wang PC, Liang XJ. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. NANOSCALE 2013; 5:8307-8325. [PMID: 23860639 PMCID: PMC3934102 DOI: 10.1039/c3nr01525d] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
The advent of nanotechnology has reignited interest in the field of pharmaceutical science for the development of nanomedicine. Nanomedicinal formulations are nanometer-sized carrier materials designed for increasing the drug tissue bioavailability, thereby improving the treatment of systemically applied chemotherapeutic drugs. Nanomedicine is a new approach to deliver the pharmaceuticals through different routes of administration with safer and more effective therapies compared to conventional methods. To date, various kinds of nanomaterials have been developed over the years to make delivery systems more effective for the treatment of various diseases. Even though nanomaterials have significant advantages due to their unique nanoscale properties, there are still significant challenges in the improvement and development of nanoformulations with composites and other materials. Here in this review, we highlight the nanomedicinal formulations aiming to improve the balance between the efficacy and the toxicity of therapeutic interventions through different routes of administration and how to design nanomedicine for safer and more effective ways to improve the treatment quality. We also emphasize the environmental and health prospects of nanomaterials for human health care.
Collapse
Affiliation(s)
- Anil Kumar
- CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, No. 11, First North Road, Beijing100190, P. R. China
- University of Chinese Academy of Science, Beijing, P. R. China
| | - Fei Chen
- CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, No. 11, First North Road, Beijing100190, P. R. China
- University of Chinese Academy of Science, Beijing, P. R. China
| | - Anbu Mozhi
- CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, No. 11, First North Road, Beijing100190, P. R. China
- University of Chinese Academy of Science, Beijing, P. R. China
| | - Xu Zhang
- CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, No. 11, First North Road, Beijing100190, P. R. China
| | - Yuanyuan Zhao
- CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, No. 11, First North Road, Beijing100190, P. R. China
| | - Xiangdong Xue
- CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, No. 11, First North Road, Beijing100190, P. R. China
- University of Chinese Academy of Science, Beijing, P. R. China
| | - Yanli Hao
- Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, China
| | - Xiaoning Zhang
- Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, China
| | - Paul C. Wang
- Laboratory of Molecular Imaging, Department of Radiology, Howard University, Washington DC 20060, USA
| | - Xing-Jie Liang
- CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, No. 11, First North Road, Beijing100190, P. R. China
| |
Collapse
|
541
|
Morton SW, Herlihy KP, Shopsowitz KE, Deng J, Chu KS, Bowerman CJ, DeSimone JM, Hammond PT. Scalable manufacture of built-to-order nanomedicine: spray-assisted layer-by-layer functionalization of PRINT nanoparticles. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2013; 25:4707-13. [PMID: 23813892 PMCID: PMC4040353 DOI: 10.1002/adma.201302025] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2013] [Indexed: 05/20/2023]
Abstract
Scalable methods, PRINT particle fabrication, and spray-assisted Layer-by-Layer deposition are combined to generate uniform and functional nanotechnologies with precise control over composition, size, shape, and surface functionality. A modular and tunable approach towards design of built-to-order nanoparticle systems, spray coating on PRINT particles is demonstrated to achieve technologies capable of targeted interactions with cancer cells for applications in drug delivery.
Collapse
Affiliation(s)
- Stephen W. Morton
- Koch Institute for Integrative Cancer Research Department of Chemical Engineering Massachusetts Institute of Technology 77 Massachusetts Avenue, Cambridge, MA 02139 (USA)
| | - Kevin P. Herlihy
- University of North Carolina at Chapel Hill 257 Caudill Labs, South Road, Chapel Hill, North Carolina 27514 (USA)
| | - Kevin E. Shopsowitz
- Koch Institute for Integrative Cancer Research Department of Chemical Engineering Massachusetts Institute of Technology 77 Massachusetts Avenue, Cambridge, MA 02139 (USA)
| | - Jason Deng
- Koch Institute for Integrative Cancer Research Department of Chemical Engineering Massachusetts Institute of Technology 77 Massachusetts Avenue, Cambridge, MA 02139 (USA)
| | - Kevin S. Chu
- University of North Carolina at Chapel Hill 257 Caudill Labs, South Road, Chapel Hill, North Carolina 27514 (USA)
| | - Charles J. Bowerman
- University of North Carolina at Chapel Hill 257 Caudill Labs, South Road, Chapel Hill, North Carolina 27514 (USA)
| | | | | |
Collapse
|
542
|
Vanić Ž, Škalko-Basnet N. Nanopharmaceuticals for improved topical vaginal therapy: Can they deliver? Eur J Pharm Sci 2013; 50:29-41. [DOI: 10.1016/j.ejps.2013.04.035] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2012] [Revised: 04/16/2013] [Accepted: 04/26/2013] [Indexed: 11/29/2022]
|
543
|
van der Meel R, Oliveira S, Altintas I, Heukers R, Pieters EHE, van Bergen en Henegouwen PMP, Storm G, Hennink WE, Kok RJ, Schiffelers RM. Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways. Mol Pharm 2013; 10:3717-27. [PMID: 23889133 DOI: 10.1021/mp400212v] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The clinical efficacy of epidermal growth factor receptor (EGFR)-targeted inhibitors is limited due to resistance mechanisms of the tumor such as activation of compensatory pathways. Crosstalk between EGFR and insulin-like growth factor 1 (IGF-1R) signaling has been frequently described to be involved in tumor proliferation and resistance. One of the attractive features of nanomedicines is the possibility to codeliver agents that inhibit different molecular targets in one nanocarrier system, thereby strengthening the antitumor effects of the individual agents. Additionally, exposure to healthy tissues and related unwanted side-effects can be reduced. To this end, we have recently developed anti-EGFR nanobody (Nb)-liposomes loaded with the anti-IGF-1R kinase inhibitor AG538, which showed promising antiproliferative effects in vitro. In the present study, we have further evaluated the potential of this dual-active nanomedicine in vitro and for the first time in vivo. As intended, the nanomedicine inhibited EGFR and IGF-1R signaling and subsequent activation of downstream cell proliferation and survival pathways. The degree of inhibition induced by the nanomedicine on a molecular level correlated with cytotoxicity in tumor cell proliferation assays and may even be predictive of the response to nanomedicine treatment in tumor xenograft models. Combination therapy with kinase inhibitor-loaded Nb-liposomes is therefore an appealing strategy for inhibiting the proliferation of tumors that are highly dependent on EGFR and IGF-1R signaling.
Collapse
Affiliation(s)
- Roy van der Meel
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University , Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
544
|
Cabrera I, Elizondo E, Esteban O, Corchero JL, Melgarejo M, Pulido D, Córdoba A, Moreno E, Unzueta U, Vazquez E, Abasolo I, Schwartz S, Villaverde A, Albericio F, Royo M, García-Parajo MF, Ventosa N, Veciana J. Multifunctional nanovesicle-bioactive conjugates prepared by a one-step scalable method using CO2-expanded solvents. NANO LETTERS 2013; 13:3766-74. [PMID: 23829208 DOI: 10.1021/nl4017072] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
The integration of therapeutic biomolecules, such as proteins and peptides, in nanovesicles is a widely used strategy to improve their stability and efficacy. However, the translation of these promising nanotherapeutics to clinical tests is still challenged by the complexity involved in the preparation of functional nanovesicles and their reproducibility, scalability, and cost production. Here we introduce a simple one-step methodology based on the use of CO2-expanded solvents to prepare multifunctional nanovesicle-bioactive conjugates. We demonstrate high vesicle-to-vesicle homogeneity in terms of size and lamellarity, batch-to-batch consistency, and reproducibility upon scaling-up. Importantly, the procedure is readily amenable to the integration/encapsulation of multiple components into the nanovesicles in a single step and yields sufficient quantities for clinical research. The simplicity, reproducibility, and scalability render this one-step fabrication process ideal for the rapid and low-cost translation of nanomedicine candidates from the bench to the clinic.
Collapse
Affiliation(s)
- Ingrid Cabrera
- Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus Universitari de Bellaterra, 08193 Cerdanyola del Vallès, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
545
|
Bala V, Rao S, Boyd BJ, Prestidge CA. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release 2013; 172:48-61. [PMID: 23928356 DOI: 10.1016/j.jconrel.2013.07.022] [Citation(s) in RCA: 150] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 07/19/2013] [Accepted: 07/20/2013] [Indexed: 10/26/2022]
Abstract
SN38 (7-ethyl-10-hydroxy camptothecin) is a prominent and efficacious anticancer agent. It is poorly soluble in both water and pharmaceutically approved solvents; therefore, the direct formulation of SN38 in solution form is limited. Currently, the water soluble prodrug of SN38, irinotecan (CPT-11), is formulated as a low pH solution and is approved for chemotherapy. However, CPT-11, along with most other water-soluble prodrugs shows unpredictable inter-patient conversion to SN38 in vivo, instability in the physiological environment and variable dose-related toxicities. More recently, macromolecular prodrugs (i.e. EZN-2208, IMMU-130) and nanomedicine formulations (i.e. nanoemulsions, polymeric micelles, lipid nanocapsule/nanoparticle, and liposomes) of SN38 have been investigated for improved delivery to cancer cells and tissues. Specifically, these carriers can take advantage of the EPR effect to direct drug preferentially to tumour tissues, thereby substantially improving efficacy and minimising side effects. Furthermore, oral delivery has been shown to be possible in preclinical results using nanomedicine formulations (i.e. dendrimers, lipid nanocapsules, polymeric micelles). This review summarizes the recent advances for the delivery of SN38 with a focus on macromolecular prodrugs and nanomedicines.
Collapse
Affiliation(s)
- Vaskor Bala
- Ian Wark Research Institute, University of South Australia, Mawson Lakes, SA, Australia
| | - Shasha Rao
- Ian Wark Research Institute, University of South Australia, Mawson Lakes, SA, Australia
| | - Ben J Boyd
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, VIC, Australia
| | - Clive A Prestidge
- Ian Wark Research Institute, University of South Australia, Mawson Lakes, SA, Australia.
| |
Collapse
|
546
|
Gonçalves G, Vila M, Portolés MT, Vallet-Regi M, Gracio J, Marques PAAP. Nano-graphene oxide: a potential multifunctional platform for cancer therapy. Adv Healthc Mater 2013; 2:1072-90. [PMID: 23526812 DOI: 10.1002/adhm.201300023] [Citation(s) in RCA: 112] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Indexed: 11/09/2022]
Abstract
Nano-GO is a graphene derivative with a 2D atomic layer of sp² bonded carbon atoms in hexagonal conformation together with sp³ domains with carbon atoms linked to oxygen functional groups. The supremacy of nano-GO resides essentially in its own intrinsic chemical and physical structure, which confers an extraordinary chemical versatility, high aspect ratio and unusual physical properties. The chemical versatility of nano-GO arises from the oxygen functional groups on the carbon structure that make possible its relatively easy functionalization, under mild conditions, with organic molecules or biological structures in covalent or non-covalent linkage. The synergistic effects resulting from the assembly of well-defined structures at nano-GO surface, in addition to its intrinsic optical, mechanical and electronic properties, allow the development of new multifunctional hybrid materials with a high potential in multimodal cancer therapy. Herein, a comprehensive review of the fundamental properties of nano-GO requirements for cancer therapy and the first developments of nano-GO as a platform for this purpose is presented.
Collapse
Affiliation(s)
- Gil Gonçalves
- TEMA-NRD, Mechanical Engineering Department and Aveiro Institute of Nanotechnology (AIN), University of Aveiro, 3810-193 Aveiro, Portugal.
| | | | | | | | | | | |
Collapse
|
547
|
Liu X, Chen Y, Li H, Huang N, Jin Q, Ren K, Ji J. Enhanced retention and cellular uptake of nanoparticles in tumors by controlling their aggregation behavior. ACS NANO 2013; 7:6244-6257. [PMID: 23799860 DOI: 10.1021/nn402201w] [Citation(s) in RCA: 245] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Effective accumulation of nanoparticles (NPs) in tumors is crucial for NP-assisted cancer diagnosis and treatment. With the hypothesis that aggregation of NPs stimulated by tumor microenvironment can be utilized to enhance retention and cellular uptake of NPs in tumors, we designed a smart NP system to evaluate the effect of aggregation on NPs' accumulation in tumor tissue. Gold nanoparticles (AuNPs, ~16 nm) were facilely prepared by surface modification with mixed-charge zwitterionic self-assembled monolayers, which can be stable at the pH of blood and normal tissues but aggregate instantly in response to the acidic extracellular pH of solid tumors. The zwitterionic AuNPs exhibited fast, ultrasensitive, and reversible response to the pH change from pH 7.4 to pH 6.5, which enabled the AuNPs to be well dispersed at pH 7.4 with excellent stealth ability to resist uptake by macrophages, while quickly aggregating at pH 6.5, leading to greatly enhanced uptake by cancer cells. An in vivo study demonstrated that the zwitterionic AuNPs had a considerable blood half-life with much higher tumor accumulation, retention, and cellular internalization than nonsensitive PEGylated AuNPs. A preliminary photothermal tumor ablation evaluation suggested the aggregation of AuNPs can be applied to cancer NIR photothermal therapy. These results suggest that controlled aggregation of NPs sensitive to tumor microenvironment can serve as a universal strategy to enhance the retention and cellular uptake of inorganic NPs in tumors, and modifying NPs with a mixed-charge zwitterionic surface can provide an easy way to obtain stealth properties and pH-sensitivity at the same time.
Collapse
Affiliation(s)
- Xiangsheng Liu
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China
| | | | | | | | | | | | | |
Collapse
|
548
|
Savage DJ, Liu X, Curley SA, Ferrari M, Serda RE. Porous silicon advances in drug delivery and immunotherapy. Curr Opin Pharmacol 2013; 13:834-41. [PMID: 23845260 DOI: 10.1016/j.coph.2013.06.006] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2013] [Revised: 06/14/2013] [Accepted: 06/17/2013] [Indexed: 12/31/2022]
Abstract
Biomedical applications of porous silicon include drug delivery, imaging, diagnostics and immunotherapy. This review summarizes new silicon particle fabrication techniques, dynamics of cellular transport, advances in the multistage vector approach to drug delivery, and the use of porous silicon as immune adjuvants. Recent findings support superior therapeutic efficacy of the multistage vector approach over single particle drug delivery systems in mouse models of ovarian and breast cancer. With respect to vaccine development, multivalent presentation of pathogen-associated molecular patterns on the particle surface creates powerful platforms for immunotherapy, with the porous matrix able to carry both antigens and immune modulators.
Collapse
Affiliation(s)
- David J Savage
- Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA; MD Anderson Cancer Center, Department of Surgical Oncology, 1515 Holcombe Blvd #444, Houston, TX, USA; The University of Texas Medical School at Houston, 6431 Fannin, Houston, TX, USA
| | | | | | | | | |
Collapse
|
549
|
Maeda H. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci 2013; 104:779-89. [PMID: 23495730 PMCID: PMC7657157 DOI: 10.1111/cas.12152] [Citation(s) in RCA: 117] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Accepted: 03/10/2013] [Indexed: 12/16/2022] Open
Abstract
This review focuses primarily on my own research, including pathogenic mechanisms of microbial infection, vascular permeability in infection and tumors, and effects of nitric oxide (NO), superoxide anion radical (O₂⁻), and 8-nitroguanosine in the enhanced permeability and retention (EPR) effect for the tumor-selective delivery of macromolecular agents (nanomedicines). Infection-induced vascular permeability is mediated by activation of the kinin-generating protease cascade (kallikrein-kinin) triggered by exogenous microbial proteases. A similar mechanism operates in cancer tissues and in carcinomatosis of the pleural and peritoneal cavities. Infection also stimulates O₂⁻ generation via activation of xanthine oxidase while generating NO by inducing NO synthase. These chemicals function in mutation and carcinogenesis and promote inflammation, in which peroxynitrite (a product of O₂⁻ and NO) activates MMP, damages DNA and RNA, and regenerates 8-nitroguanosine and 8-oxoguanosine. We showed vascular permeability by using macromolecular drugs, which are not simply extravasated through the vascular wall into the tumor interstitium but remain there for prolonged periods. We thus discovered the EPR effect, which led to the rational development of tumor-selective delivery of polymer conjugates, micellar and liposomal drugs, and genes. Our styrene-maleic acid copolymer conjugated with neocarzinostatin was the first agent of its kind used to treat hepatoma. The EPR effect occurs not only because of defective vascular architecture but also through the generation of various vascular mediators such as kinin, NO, and vascular endothelial growth factor. Although most solid tumors, including human tumors, show the EPR effect, heterogeneity of tumor tissue may impede drug delivery. This review describes the barriers and countermeasures for improved drug delivery to tumors by using nanomedicines.
Collapse
Affiliation(s)
- Hiroshi Maeda
- Institute of Drug Delivery System Research, Sojo University, Kumamoto, Japan.
| |
Collapse
|
550
|
Targeting nanotherapeutics to the tumor microenvironment: how accurately can we aim? Ther Deliv 2013; 4:771-3. [DOI: 10.4155/tde.13.56] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|